Boston Scientific warns cyberattack will derail 2026 growth targets and quarterly results

BSX has warned that a cyberattack will keep it from meeting its 2026 growth targets and will weigh on quarterly results. The company has flagged the shortfall without yet issuing revised numbers, deferring the actual guidance update to its third-quarter call on October 28.

Context that changes how large the incremental damage looks: Boston Scientific's full-year growth guidance had already been cut once this year, from an original 6.5% to 8% range down to 5.5% to 6.5%, before the cyberattack occurred. So this is a second reduction layered on a first, not a single break in an otherwise intact outlook, and coverage that presents the attack as derailing the original target compresses two separate events into one.

Shares fell on the disclosure, though the reported magnitude varies with the timestamp: premarket quotes showed declines of roughly 4.5%, with around 2.1% cited for the move before the bell. The dispersion is a reason to treat any single figure as a snapshot rather than the day's verdict.

For a medical-device manufacturer, a cyber incident is an operational problem more than a data one: order intake, manufacturing scheduling and hospital delivery all run through systems that have to be taken offline to be remediated, and revenue lost to a delayed shipment does not fully come back. What to watch: the specific revised guidance range on October 28, whether the company quantifies the revenue impact separately from ordinary demand, and whether remediation is described as complete by then.

Related Stocks

• BSX